Investigator
GlaxoSmithKline
Disclosure: GlaxoSmithKline (Employee, Shareholder)
Pan Chan has over 20 years scientific experience working at GlaxoSmithKline on Infectious Diseases drug discovery programs. He has numerous publications in impactful journals including on the mechanism of action of gepotidacin. Pan completed his PhD research on bacterial quorum signalling at Nottingham Univerisity and postdoc on S.aureus pathogenicity at Sheffield University, UK. He joined GSK in Collegeville, US where he was responsible for target validation and compound mechanism of action studies to support GSK's portfolio of novel antibacterial targets. He has been biology leads on early antibacterial drug discovery programs and has managed academic collaborations. Currently, he is a project lead on a novel host target associated with infectious disease. He is active member of both GSK Fellows and GSK Biology Council with roles to increase scientific engagement in the GSK biology community.
